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Abstract
The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for hepatocellular carcinoma
(HCC) are still insufﬁcient. Thus, accurate risk prediction of cancer development in individual patients with the aim of selecting high risk
cohorts of patients for HCC chemoprevention programs remains an elusive goal. Future directions in chemoprevention of HCC will be in
the development of molecular risk models and of new chemopreventive agents. Studies examining multiple genes and proteins (genomics and
proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. A strategy aiming at preventing chronic liver disease
of any etiology (HCV and HBV infection, alcohol, obesity, others) may be required to prevent HCC in low and intermediate incidence areas,
and hence, worldwide. In the setting of secondary chemoprevention, literature data pooling suggests a slight preventive effect of interferon
(IFN) on HCC development in patients with HCV-related cirrhosis. The magnitude of this effect is low, and the observed beneﬁt might be due
to spurious associations. The preventive effect is limited to sustained virological responders to IFN. So, there is no sound evidence to support
a recommendation for widespread use of IFN to prevent HCC in HCV-related cirrhosis. In the setting of tertiary chemoprevention, the risk of
recurrence of HCC may be reduced by IFN treatment in selected patient populations. Further large-scale multicenter randomized controlled
trials may prove useful to evaluate the beneﬁt on overall survival.
© 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Keywords: Chemoprevention; Hepatocellular carcinoma
1. Introduction
Although early diagnosis and effective treatments are
paramount in controlling the death rate of patients with
hepatocellular carcinoma (HCC) [1], the importance of cancer
prevention has gradually emerged because advanced (large
or locally invasive) HCC is difﬁcult to cure [2]. Because
the basic mechanism of all cancer development results from
accumulation of epigenetic and genetic alterations in cells, the
current concept of multistage carcinogenesis has promoted
chemoprevention to the stage of a new medical science [3].
Therefore, HCC (chemo)prevention remains a major issue in
the long-term management of cirrhotic patients, especially in
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compensated cirrhosis of viral aetiology, in which HCC is the
ﬁrst complication to occur and a major cause of liver-related
death [4].
Chemoprevention may be deﬁned as the use of natural or
synthetic agents to reverse, suppress, or prevent premalignant
lesions from progressing to invasive cancer [5]. Chemopre-
vention of HCC may be classiﬁed into three categories:
1. primary, preventing cancer in healthy subjects at high risk
for etiologic factors known to cause chronic liver disease;
2. secondary, preventing cancer in those with premalignant
conditions, for example, HCC prevention in patients with
cirrhosis;
3. tertiary, preventing recurrence in patients cured of an
initial cancer.
A prevention program for HCC should fulﬁl the following
prerequisites:
1. identiﬁcation of the risk factors for HCC;
2. determination of the pathogenetic mechanisms of liver
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carcinogenesis as well as of the genetic markers that
identify the early events in the carcinogenetic process and
possibly availability of animal tumor models;
3. ﬁnally, evaluation of the available data from epidemiologic
and clinical studies on candidate (chemo)preventive agents.
2. Primary prevention
Because vaccination against HCV is yet unavailable and
there is only a low probability of a vaccine against HCV being
developed in the near future, other preventive methods are
required to reduce the burden of HCV-related liver disease.
Counselling is needed for primary prevention of new infection
by rigorous implementation of infection control practice to
prevent nosocomial and iatrogenic HCV transmission and
secondary prevention of HCV transmission from infected
persons to other persons [6]. However, the impact of any
prevention program on HCV spread is relatively low because
the majority of the infected patients are not under medical
care. Although screening of the whole population is not
recommended, it is important to test for HCV all persons with
risk factors for HCV infection. A strategy aiming at preventing
chronic liver disease of any etiology (alcohol, obesity, others)
may be required to prevent HCC in low- and intermediate-
incidence areas, and hence, worldwide. The incidence of
HCC might be further reduced by eliminating aﬂatoxin from
the food supply in areas of the world where agricultural
products are stored under conditions that favour the growth
of Aspergillus ﬂavus and Aspergillus parasiticus. A recent
case-control study conducted in Sudan clearly demonstrated
that reduction of aﬂatoxin contamination of foods may be a
useful public health strategy in HCC prevention [7]. Other
risk factors, like anabolic or sex steroids, smoking habits,
and perhaps plant-derived or chemical agents have not been
considered, because their impact on HCC epidemiology is
doubtful or very small, and available data are sparse and
somewhat conﬂicting.
3. Secondary prevention
The role of interferon (IFN) in preventing HCC in HCV
related cirrhosis is controversial. It has been argued that long-
term suppression of viral replication could reduce hepatocyte
turnover and lessen the risk of dysplasia and cancer. In 1995,
a small randomized controlled trial (RCT) showed a decrease
in the incidence of HCC in patients with HCV cirrhosis
compared with untreated controls [8]. In the wake of this
study, several controlled trials [9–27] were performed. These
studies, often assessed retrospectively, collected cohorts of
a relatively small size and having a marked degree of
heterogeneity, making it difﬁcult to assess the actual level of
beneﬁt obtained by IFN treatment. Moreover, these studies
have been subjected to many criticisms because of several
methodological ﬂaws, their results being largely inconsistent.
This can be explained, at least in part, by differences in
design, stage of disease, duration of follow up, type of
IFN, and schedule of treatment. The main reason for these
discrepancies, however, most likely derives from the many
limitations of retrospective studies, such as susceptibility,
intervention, and selection biases, that may make the results
unreliable. Finally these studies were not primarily designed,
powered and conducted to assess the beneﬁt of IFN on HCC
prevention.
Hitherto, a number of important questions still remain
unsolved by the available studies:
– Is the risk of HCC in viral cirrhosis reduced by IFN
therapy?
– If a risk reduction truly exists, does the beneﬁt apply to all
patients with HCV cirrhosis?
– Is a sustained response to IFN required to reduce the
incidence of HCC?
– Does the preventive effect of IFN on HCC development
start before the onset of severe ﬁbrosis or cirrhosis?
Three meta-analyses on aggregate data [28–30] were
performed to evaluate whether IFN reduces the incidence
of HCC in patients with HCV-related cirrhosis. In the last
published [30], IFN seemingly decreased HCC rate in all but
one of 20 studies included in the meta-analysis, a signiﬁcant
difference being observed in 13 studies.
The rate difference (RD) between IFN-treated patients and
controls of each trial ranged from −33.3% to +3.9%. The
pooled estimate of the treatment effect was signiﬁcantly in
favour of a preventive effectiveness of IFN (RD, −12.2%;
95% CI, −8.4% to −16.1%, P < 0.00001). A remarkable
heterogeneity among the studies (P < 0.0001) was found.
The most prominent heterogeneity was in the difference of
magnitude of the treatment effect on the risk of cancer (“quan-
titative heterogeneity”). Large differences were observed in
the baseline risk of HCC among the different trials: the HCC
rate in the untreated group ranged from 6.8% to 73%.
All meta-analyses [28–30] clearly showed that the hetero-
geneity in HCC incidence in patients who received IFN is the
most relevant feature of the studies. The inconsistency among
these trials is not surprising if one considers all potential
biases in the selection of patients with different demographic
and clinical characteristics, different timing of referral and
diagnostic criteria, true differences in case mix, risk factors
for HCC development, severity of the underlying cirrhosis
and dose and length of IFN treatment.
An attempt to explain the wide variability in the risk of
HCC development was made by stratifying studies according
to variables that described the patients studied (patient-
level covariates) and the study design features (study-level
covariates). A signiﬁcant heterogeneity in IFN beneﬁt among
studies remained even after stratifying by study- and patient-
level covariates. However, heterogeneity in the prevention
effect of IFN on HCC development disappears in the stratum
of sustained responders, implying that viral clearance seems
to inﬂuence the clinical beneﬁt.
A meta-analysis [30] clearly showed that the overall effect
of IFN on HCC development was inﬂuenced by the Japanese
studies, which had the highest incidence of HCC in untreated
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patients. This may be explained by the intensiveness of the
screening programs. Genetic and dietary factors, different
strains of HCV, age-speciﬁc distribution of infection or HBV
occult infection and different molecular characteristics and
biological behaviour of the tumour may also account for the
difference in HCC incidence observed between European and
Japanese patients.
Firm conclusions, drawn on the results of direct com-
parisons between treated and untreated cirrhotic patients,
are seriously hampered by the fact that the majority of the
studies included in the meta-analyses were non randomized
controlled trials (NRCT) and only three small RCTs were
originally designed to perform this comparison. NRCTs are
subject to many problems that reduce their internal and ex-
ternal validity. Their lack of precision and reliability causes
inherent biases towards false positive results [31]. When as-
sessing NRCTs, the most important bias is the likelihood of
inappropriate selection of patients, which can lead to incor-
rect results and spurious associations. Therapeutic guidelines
cannot be derived from NRCTs unless the observed beneﬁt
of treatment is large, the treated group strictly comparable
to external controls, and the clinical course of untreated pa-
tients predictable by a reliable prognostic model. None of the
NRCTs of IFN for HCC prevention in viral cirrhosis fulﬁls
these methodological standards.
So, the available evidence from meta-analyses is sufﬁcient
to conclude that IFN may prevent or delay the development
of HCC in patients with HCV-related cirrhosis. However,
the magnitude of the overall effect is low and the observed
beneﬁt might be due to spurious associations. The preventive
effect is stronger among sustained responders to IFN, which
intrinsically represent a small proportion of all cirrhotic
patients.
After the meta-analyses, 3 observational cohort studies,
two prospective studies conducted in Japan [32] and in
Taiwan [33] and one retrospective study conducted in Italy
[34], have clearly conﬁrmed that the efﬁcacy of IFN in
the chemoprevention of HCC is exclusively linked to the
achievement of a sustained viral eradication, while no beneﬁt
in reducing HCC development was observed in non-responder
patients.
Recently, the effectiveness of long-term maintenance ther-
apy with pegylated-IFN at low dose in non-responder patients
with advanced ﬁbrosis or HCV-related cirrhosis was evaluated
by 3 RCTs: the HALT-C trial [35], the Epic-3 trial [36] and
the COPILOT trial [37]. Patients in these studies were quite
homogeneous in terms of recruitment criteria, stage of liver
disease at entry, follow up and treatments. The outcomes
assessed were death, hepatic decompensation as deﬁned by
Child-Pugh score progression, HCC, and, for non-cirrhotic
patients, an increase in hepatic ﬁbrosis.
Not surprisingly, in all the 3 RCTs the proportion of cir-
rhotic patients who developed clinical outcomes was similar
in the treatment and control group. The 3 studies show that
the natural history of cirrhosis was not signiﬁcantly affected
by low-dose PEG-IFN maintenance treatment as both overall,
event free survival and HCC development did not differ
between treated and untreated patients. So, no beneﬁt of
maintenance therapy in reducing the progression of ﬁbrosis,
hepatic decompensation, mortality, or in preventing the devel-
opment of HCC was observed, despite the improvement of
inﬂammatory markers (alanine aminotransferase and necroin-
ﬂammatory histologic ﬁndings) and the reduction of viral
load. It seems reasonable, therefore, to recommend caution
when treating cirrhotic patients to reduce the risk of cancer
with long-term maintenance IFN regimens.
The negative results of these large multicentre RCTs were
fully expected, based on the following considerations:
First, the hypothesis that a long-term suppression of HCV
replication in the absence of a complete viral eradication
could slow or block the mechanisms of carcinogenesis has
low biological plausibility. In contrast to the data regarding
carcinogenesis by HBV, there is currently no sound evidence
in the literature that the risk of developing HCC is correlated
with the levels of HCV replication.
Second, our previous meta-analysis [38] had already
clearly demonstrated that the histological improvement of
ﬁbrosis was clearly observed only in patients with a sustained
virological response to therapy while in nonresponders we did
not ﬁnd any signiﬁcant regression of ﬁbrosis.
Third, previous evidence from literature data pooling
clearly suggested that the preventive effect of IFN on HCC
development in patients with HCV-related cirrhosis was
observed only among sustained responders to IFN.
Fourth, the low doses of PEG-IFN used in the 3 RCTs
make the probability of demonstrating a signiﬁcant clinical
beneﬁt very unlikely.
Finally, considering the difﬁculties in planning and con-
ducting long-term randomised clinical trials, a prospective
trial aimed at assessing the efﬁcacy of IFN in preventing HCC
should have been conducted in a selected population at high
risk for HCC development.
4. Tertiary chemoprevention
The 3-year survival rate of patients with HCC undergoing
surgical or percutaneous ablation remains low, because of the
high risk of intra-hepatic recurrence even though treatment
has been considered curative by imaging technique. A plateau
in the effectiveness of ablative treatment may well have
been reached, and further improvement in survival from a
single-modality approach seems unlikely.
Cammà et al. [39] who followed a large cohort (more than
200) of patients with small (<5 cm) HCC in compensated
cirrhosis treated by radiofrequency thermal ablation (RFTA),
reported that the 3-year recurrence rate of new lesions was
34%, quite similar to that of a previous study on percutaneous
ethanol injection (PEI) (41%) of the same group [40], and
also similar to that found in the study by Lencioni et al.
[41], in which the 2-year recurrence rate of patients treated by
radiofrequency thermal ablation was 36%. Therefore, all these
data underscore, from a practical point of view, the need for
adjuvant therapy (tertiary prevention) in the effort to prolong
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survival and reduce recurrence rates. In the past, different
anticancer agents have been evaluated for tertiary prevention
of HCC recurrence, including retinoids [42], intra-arterial
I-131 [43], adoptive immunotherapy [44], and ﬁnally IFN
[45–49]. Recently, sorafenib, an oral multi-kinase inhibitor
targeting both tumor cells and the tumor vasculature is
being evaluated in the setting of tertiary chemoprevention.
Two large multinational randomized, double blind, placebo-
controlled trials are currently in progress to evaluate the
efﬁcacy (overall survival and cancer-free survival) and the
tolerability of sorafenib versus placebo as adjuvant treatment
in subjects with HCC following potentially curative treatment
(surgical resection or local ablation) or palliative treatment
(transcatheter arterial chemoembolization – TACE).
5. Interferon
The potential activity of IFN in the setting of secondary
chemoprevention has led to the treatment of patients with
IFN in the adjuvant setting. Since the ﬁrst RCT of IFN
adjuvant therapy appeared in 2000 [45], four other RCTs
have been published [46–49]. Studies have indicated that IFN
decreases the rate of HCC recurrence, and the results of
our meta-analysis, totalling 196 patients, consistently show
a statistically signiﬁcant beneﬁt on HCC recurrence. IFN
was superior to no treatment in all trials, reaching statistical
signiﬁcance in all but one study. The pooled estimate of the
treatment effect was signiﬁcantly in favour of a beneﬁcial
effect of IFN on HCC recurrence (RD, −43%; 95% CI,
−65% to −20%, P < 0.0001). No signiﬁcant heterogeneity
was found among the ﬁve trials. The NNT, i.e. the number
of patients with HCC receiving potentially curative treatments
needed to treat with IFN to prevent one cancer recurrence,
was 2. However, the key clinical question is whether all
patients with HCC receiving potentially curative treatments
should and could be treated with IFN or whether adjuvant
treatment should be administered only to a selected group of
patients who clearly stand to beneﬁt. Unfortunately, there is
no reliable predictive model capable of identifying patients
with HCC receiving potentially curative treatments at high
risk of developing HCC recurrence. Furthermore, all the
RCTs in the tertiary setting have been conducted in the
eastern populations limiting the external validity of these
studies and therefore making the transferability of the results
to different populations questionable. Further large-scale
multicenter RCTs designed and conducted also in western
populations may prove useful to substantiate the beneﬁt on
recurrence and overall survival.
Recently, Mazzaferro and coworkers published a RCT [50]
on a group of 150 early or intermediate HCV-related HCC
patients undergoing resection and stratiﬁed into 80 HCV-
pure (hepatitis B anticore antibody [anti-HBc]-negative) and
70 HCV mixed (anti-HBc-positive) groups, then randomized
to IFN-α (3 million units 3 times weekly for 48 weeks
[n = 76]) versus control (n = 74). While no treatment effect
was apparent in the mixed HCV + HBV population and
on early recurrences, there was a signiﬁcant beneﬁt on
late recurrences in HCV-pure patients adherent to treatment.
Authors concluded that IFN does not affect overall prevention
of HCC recurrence after resection, but it may reduce late
recurrence in HCV-pure patients receiving effective treatment.
6. Acyclic retinoids
Retinoids, acting on nuclear receptors, retinoic acid recep-
tor (RAR) and retinoid X receptor (RXR) have potential for
cancer chemoprevention through their action as regulators of
cell growth and differentiation [51]. Retinoids may inhibit or
reverse the carcinogenic process in various types of cancers,
including the liver, in experimental models of oncogenesis.
A preventive approach to HCC using a synthetic retinoid
analog, acyclic retinoid, has theoretical interest, because post-
translational modiﬁcation of RXR by phosphorylation impairs
its function, leading to uncontrolled hepatocyte growth. In
vitro acyclic retinoid suppresses the phosphorylation of nu-
clear retinoid X receptor α (RXRα), restores its function in the
presence of its endogenous ligand, 9-cis RA, and thereby in-
duces apoptosis of the cancer cells. HCC in cirrhotic patients
contains lower levels of endogenous retinoids, and may be
insensitive to retinoic acid because of a malfunction of RXRα
[50]. In HCC tissues, there is an accumulation of phospho-
inactivated RXRα, which functions as a dominant negative
receptor and interferes with transactivation by remaining
normal RXRα. Acyclic retinoid prevents phosphorylation of
RXRα and restores its function and enhances the sensitivity
of HCC cells to IFNs-α and -β, thereby promoting apoptosis
induced by these interferons. This could lead to eradication
of (pre)malignant clones (“clonal deletion”) from the cirrhotic
liver.
Clinical use of polyprenoic acid, an orally absorbable
acyclic retinoid, has been exploited in the context of tertiary
prevention of HCC recurrence after surgical or PEI tumor
ablation in 89 patients with cirrhosis [52]. Treatment with
polyprenoic acid signiﬁcantly reduced the incidence of re-
current or new cancer lesions. After a median follow-up of
38 months, 12 patients in the polyprenoic acid group (27%)
had recurrent or new HCCs compared with 22 patients in the
placebo group (49%, P = 0.04). These promising results still
await conﬁrmation by other controlled studies.
7. Summary
The accuracy and the reliability of well-recognized clin-
ical, virologic, histologic, and molecular risk factors for
HCC are still insufﬁcient; thus, accurate risk prediction of
developing cancer in individual patients remains an elu-
sive goal. Future directions in chemoprevention of HCC
will be in the development of new molecular risk models
and of new chemopreventive agents. The design of targeted
molecular therapies may need to be tailored to the speciﬁc
molecular phenotype of a speciﬁc HCC. Studies examining
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multiple genes and proteins (genomics and proteomics) in
the same HCCs will be required to evaluate this possibility
thoroughly.
In the setting of secondary chemoprevention, literature
data pooling suggests a slight preventive effect of IFN on
HCC development in patients with HCV-related cirrhosis. The
magnitude of this effect is low, and the observed beneﬁt might
be due to spurious associations. The preventive effect is more
evident among sustained responders to IFN.
In the setting of tertiary chemoprevention, although dif-
ferent agents have been evaluated including retinoids, intra-
arterial I-131, adoptive immunotherapy, and ﬁnally IFN, there
is no sound evidence to support the recommendation for
widespread use of these agents to prevent HCC recurrence
after curative or palliative treatments. The risk of recurrence
of HCC seems reduced by IFN treatment in selected orien-
tal populations only. However, the results are on the whole
inconclusive or conﬂicting and they were not replicated in
most cases. The lack of conclusive evidence of beneﬁt from
the previous therapeutic approaches highlights the urgent and
ongoing need for more effective and safe adjuvant agents
assessed in large-scale multicenter RCTs. Sorafenib is being
evaluated in 2 RCTs designed to assess the effectiveness
of this drug in improving overall survival of patients with
HCC undergoing surgical resection, RFTA or TACE. It is,
therefore, necessary to wait for the results of these RCTs to
implement efﬁcient programs of tertiary chemoprevention in
clinical practice.
Conﬂicts of interest
The authors have received a fee from Bayer HealthCare
for their contribution to this supplement. Bayer HealthCare
played no role in the preparation, review, or approval of the
manuscript. The authors have no other conﬂict of interest to
report.
References
[1] Sangiovanni A, Del ninno E, Fasani P, et al. Increased survival of cir-
rhotic patients with a hepatocellular carcinoma detected during surveil-
lance. Gastroenterology 2004;126:1005–14
[2] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet
2003;362:1907–17.
[3] Lippman SM, Hong WK. Cancer prevention by delay. Commentary re:
J.A. O’Shaughnessy et al. Treatment and prevention of intraepithelial
neoplasia: an important target for accelerated new agent development.
Clin Cancer Res 2002;8:305–13.
[4] Benvegnù L, Gios M, Boccato S, et al. Natural history of compensated
viral cirrhosis: a prospective study on the incidence and hierarchy of
major complications. Gut 2004;53:744–9.
[5] Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical
carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed
Proc 1976;35:1332–8 [review].
[6] Kew M, Francois G, Lavanchy D, et al, Viral Hepatitis Preven-
tion Board. Prevention of hepatitis C virus infection. J Viral Hepat
2004;11:198–205 [review].
[7] Omer RE, Kuijsten A, Kadaru AM, et al. Population-attributable risk
of dietary aﬂatoxins and hepatitis B virus infection with respect to
hepatocellular carcinoma. Nutr Cancer 2004;48:549 15–21.
[8] Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects
of interferon-a on incidence of hepatocellular carcinoma in chronic
active hepatitis C with cirrhosis. Lancet 1995;346:1051–5.
[9] Mazzella G, Accogli E, Sottili S, et al. Alpha-interferon treatment
may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J
Hepatol 1996;24:141–7.
[10] Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes
and risk of hepatocellular carcinoma in cirrhosis: a prospective study.
Hepatology 1997;25:754–8.
[11] Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in
compensated cirrhosis type C: a retrospective follow-up study of 384
patients. Gastroenterology 1997;112:463–72.
[12] International Interferon-alpha Hepatocellular Carcinoma Study Group.
Effect of interferon-alpha on progression of cirrhosis to hepatocellular
carcinoma: a retrospective cohort study. Lancet 1998;351:1535–9.
[13] Imai Y, Kawata S, Tamura S, et al, for the Osaka Hepatocellular
Carcinoma Prevention Study Group. Relation of interferon therapy and
hepatocellular carcinoma in patients with chronic hepatitis C. Ann
Intern Med 1998;129:94–9.
[14] Gramenzi A, Andreone P, Fiorino S, et al. Impact of interferon therapy
on the natural history of HCV-related cirrhosis. Gut 2001;48:843–8.
[15] Serfaty L, Aumaître H, Cazouillères O, et al. Determinants of out-
come of compensated hepatitis C virus-related cirrhosis. Hepatology
1998;27:1435–40.
[16] Soﬁa S, Casali A, Buscarini E, et al. Effect of lymphoblastoid IFN
in the treatment of liver cirrhosis and prevention of HCC. Ital J
Gastroenterol Hepatol 1998;30:A31.
[17] Benvegnù L, Chemello L, Noventa F, et al. Retrospective analysis of
the effect of interferon therapy on the clinical outcome of patients with
viral cirrhosis. Cancer 1998;83:901–9.
[18] Shioda A, Moriyama M, Kaneko M, et al. Long-term prognosis
of hepatocellular carcinoma developing after treatment of interferon
in patients with chronic hepatitis C and liver cirrhosis. Hepatology
1999;30:268A.
[19] Yoshida H, Shiratori Y, Moriyama M, et al, for the IHIT Study
Group. Interferon therapy reduces the risk for hepatocellular carcinoma:
national surveillance program of cirrhotic and non-cirrhotic patients
with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174–81.
[20] Mura D, Deliperi R, Fastame L, et al. Five year follow-up after
Interferon therapy in HCV-positive compensated cirrhosis. Ital J Gas-
troenterol Hepatol 1998;30:A114.
[21] Valla D-C, Chevallier M, Marcellin P, et al. Treatment of hepatitis C
virus-related cirrhosis: a randomized controlled trial of interferon alfa
2b versus no treatment. Hepatology 1999;583 29:1870–5.
[22] Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate
of progression to hepatocellular carcinoma in chronic hepatitis C but
not signiﬁcantly in an advanced stage: a retrospective study in 1148
patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653–
9.
[23] Toyoda H, Kumada T, Nakano S, et al. The effect of retreatment
with interferon-alpha on the incidence of hepatocellular carcinoma in
patients with chronic hepatitis C. Cancer 2000;88:58–65.
[24] Ikeda K, Kobayashi M, Saitoh S, et al. Recurrence rate and prognosis
of patients with hepatocellular carcinoma that developed after elimina-
tion of hepatitis C virus RNA by interferon therapy. A closed cohort
study including matched control patients. Oncology 2003;65:204–10.
[25] Testino G, Ansaldi F, Andorno E, et al. Interferon therapy does not
prevent hepatocellular carcinoma in HCV compensated cirrhosis. Hep-
atogastroenterology 2002;49:1636–8.
[26] Planas R, Quer JC, Enríquez J, et al. Induction therapy with interferon
alfa-2a in compensated hepatitis C virus-related cirrhosis. Randomized,
multicenter study. Med Clin (Barc). 2002;118:641–4.
[27] Yoshida H, Tateishi R, Arakawa Y, et al. Beneﬁt of interferon therapy
in hepatocellular carcinoma prevention for individual patients with
chronic hepatitis C. Gut 2004;53:425–30.
[28] Cammà C, Giunta M, Andreone P, et al. Interferon and prevention
S292 A. Craxì, C. Cammà / Digestive and Liver Disease 42S (2010) S287–S292
of hepatocellular carcinoma in viral cirrhosis: an evidence-based ap-
proach. J Hepatol 2001;34:593–602
[29] Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect
of interferon therapy on the development of hepatocellular carcinoma
in patients with hepatitis C virus-related cirrhosis: a meta-analysis.
Aliment Pharmacol Ther 2001;15:689–98.
[30] Cammà C, Craxì A. Prevention of Hepatocellular Carcinoma. Clin
Liver Dis 2005; 9:347–51
[31] Cook TD, Campbell DT. Quasi-experimentation: design and analysis
issues for ﬁeld settings. Boston, MA: Houghton-Mifﬁn, 1979.
[32] Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic
hepatitis C: association with reduced hepatocellular carcinoma devel-
opment and improved survival. Ann Intern Med 2005;142:105–14.
[33] Yu ML, Lin SM, Lee CM, et al. A simple noninvasive index for
predicting long-term outcome of chronic hepatitis C after interferon-
based therapy. Hepatology 2006;44:1086–97.
[34] Bruno S, Stroffolini T, Colombo M, et al. Sustained virologic response
to interferon-a is associated with improved outcome in HCV-related
cirrhosis: a retrospective study. Hepatology 2007;45:579–87.
[35] DiBisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy
of advanced chronic hepatitis C with low-dose peginterferon. N Engl J
Med 2008;359:2429–41.
[36] Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and
Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon
alfa/Ribavirin Therapy. Gastroenterology 2009; 136:1618–28.
[37] Afdhal N, Levine R, Brown R Jr., et al. Colchicine versus PEG-
interferon alfa 2B long term therapy: results of the 4 year copilot trial.
J Hepatol 2008;48:S4.
[38] Cammà C, Di Bona D, Shepis F, et al. Effect of peginterferon alfa-2a
on liver histology in chronic hepatitis C: a meta-analysis of individual
patient data. Hepatology 2004;39:333–42.
[39] Cammà C, Di Marco V, Orlando A, et al. Treatment of hepatocellu-
lar carcinoma in compensated cirrhosis with radio-frequency thermal
ablation (RFTA): a prospective study. J Hepatol 2005;42:535–40.
[40] Orlando A, D’Antoni A, Camma C, et al. Treatment of small hepa-
tocellular carcinoma with percutaneous ethanol injection: a validated
prognostic model. Am J Gastroenterol 2000; 95:2921–7.
[41] Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular
carcinoma in cirrhosis: randomized comparison of radio-frequency
thermal ablation versus percutaneous ethanol injection. Radiology
2003;228:235–40.
[42] Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary
tumors by an acyclic retinoid, polyprenoic acid,in patients with hepato-
cellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med
1996;334:1561–7.
[43] Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-
labelled lipiodol for Resectable hepatocellular carcinoma: a prospective
randomised trial. Lancet 1999;353:797–801.
[44] Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy
to lower postsurgical recurrence rates of hepatocellularcarcinoma: a
randomised trial. Lancet 2000;356:802–7.
[45] Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence
of hepatocellular carcinoma after completeresection or ablation of the
primary tumor – a prospective randomized study of hepatitis C virus-
related liver cancer. Hepatology 2000;32:228–32.
[46] Kubo S, Nishiguchi S, Hirohashi K, et al. Randomized clinical trial
of long-term outcome after resection of hepatitis C virus-related hep-
atocellular carcinoma by postoperative interferon therapy. Br J Surg
2002;89:418–22.
[47] Suou T, Mitsuda A, Koda M, et al. Interferon alpha inhibits intrahepatic
recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot
study. Hepatol Res 2001;20:301–11.
[48] Miyaguchi S, Watanabe T, Takahashi H, et al. Interferon therapy for
hepatocellular carcinoma patients with low HCV-RNA levels. Hepato-
gastroenterology 2002;49:724–9.
[49] Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor
ablation improves prognosis in patients with hepatocellular carcinoma
associated with hepatitis C virus. Ann Intern Med 2003;138:299–306
[50] Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular
carcinoma recurrence with alpha-interferon after liver resection in HCV
cirrhosis. Hepatology 2006;44:1543–54.
[51] Okuno M, Kojima S, Matsushima-Nishiwaki R, et al. Retinoids in
cancer chemoprevention. Curr Cancer Drug Targets 2004;4:285–98.
[52] Kojima S, Okuno M, Matsushima-Nishiwaki R, et al. Acyclic retinoid
in the chemoprevention of hepatocellular carcinoma. Int J Oncol
2004;24:797–805.
